Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group
Abstract
Background: Brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) has demonstrated survival benefits over cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30-positive peripheral T-cell lymphoma (PTCL) in a randomized, clinical trial. However, data on the real-world effectiveness of BV-CHP in routine clinical practice remain limited.
Methods: We conducted a multicenter, retrospective cohort study of patients with newly diagnosed PTCL treated at institutions within the Gifu Hematology Study Group. Patients received BV-CHP, CHOP, or cyclophosphamide, pirarubicin, vincristine, and prednisone (THP-COP) as first-line therapy. Progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) were compared among the treatment groups. Exploratory subgroup analyses were performed, including analyses by bone marrow involvement at diagnosis.
Results: A total of 154 patients were included: 29 received BV-CHP, 72 received CHOP, and 53 received THP-COP. Overall, no significant differences were observed in PFS, OS, or ORR among the three treatment groups. In exploratory subgroup analyses, patients with bone marrow involvement who were treated with BV-CHP (n = 4) had significantly shorter PFS than those treated with CHOP (n = 17) or THP-COP (n = 15), whereas no significant difference in OS was observed.
Conclusions: In this real-world multicenter cohort from the Gifu Hematology Study Group, frontline BV-CHP did not demonstrate a survival advantage over CHOP or THP-COP in unselected patients with PTCL. These findings suggest that THP-COP remains a reasonable first-line treatment option in routine clinical practice. The inferior PFS observed in patients with bone marrow involvement treated with BV-CHP should be interpreted cautiously and warrants further investigation.
Related
- Adjuvant Docetaxel–Cyclophosphamide Versus Anthracycline–Taxane Chemotherapy in Stage I–III HR-Positive/HER2-Negative Breast Cancer: A Real-World Propensity Score Overlap-Weighted Cohort Study
- Real-World Activity and Safety of Metronomic Cyclophosphamide in Advanced Soft-Tissue Sarcoma: The Multicenter MeRCY Study
- Incident Atrial Fibrillation Following Anthracycline-Based Adjuvant Chemotherapy in Women with Breast Cancer: A Single-Centre Retrospective Cohort Study.
- Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study
- Anthracycline-Free FLA-VEN with or Without Midostaurin in Newly Diagnosed Intermediate- and Adverse-Risk AML: A Single-Center Retrospective Study.
BibTeX
@article{nakamura2026realworld,
title = {{Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group}},
author = {Nobuhiko Nakamura and Nobuhiro Kanemura and Naoki Hayase and Yuto Kaneda and Yoshikazu Ikoma and Takayuki Goto and Tomomi Suzaki and Junichi Kitagawa and Senji Kasahara and Toshiki Yamada and Michio Sawada and Kenji Fukuno and Eri Takada and Hideko Goto and Shin Lee and Kei Fujita and Tetsuji Morishita and Takeshi Hara and Hisashi Tsurumi and Masahito Shimizu},
journal = {Journal of Clinical and Experimental Hematopathology : JCEH},
year = {2026},
month = jul,
doi = {10.3960/jslrt.26008},
url = {https://doi.org/10.3960/jslrt.26008},
note = {CC BY-NC-SA 4.0},
}
RIS
TY - JOUR
TI - Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group
AU - Nobuhiko Nakamura
AU - Nobuhiro Kanemura
AU - Naoki Hayase
AU - Yuto Kaneda
AU - Yoshikazu Ikoma
AU - Takayuki Goto
AU - Tomomi Suzaki
AU - Junichi Kitagawa
AU - Senji Kasahara
AU - Toshiki Yamada
AU - Michio Sawada
AU - Kenji Fukuno
AU - Eri Takada
AU - Hideko Goto
AU - Shin Lee
AU - Kei Fujita
AU - Tetsuji Morishita
AU - Takeshi Hara
AU - Hisashi Tsurumi
AU - Masahito Shimizu
PY - 2026
DA - 2026/07/30
JO - Journal of Clinical and Experimental Hematopathology : JCEH
DO - 10.3960/jslrt.26008
UR - https://doi.org/10.3960/jslrt.26008
AB - Background: Brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) has demonstrated survival benefits over cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30-positive peripheral T-cell lymphoma (PTCL) in a randomized, clinical trial. However, data on the real-world effectiveness of BV-CHP in routine clinical practice remain limited. Methods: We conducted a multicenter, retrospective cohort study of patients with newly diagnosed PTCL treated at institutions within the Gifu Hematology Study Group. Patients received BV-CHP, CHOP, or cyclophosphamide, pirarubicin, vincristine, and prednisone (THP-COP) as first-line therapy. Progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) were compared among the treatment groups. Exploratory subgroup analyses were performed, including analyses by bone marrow involvement at diagnosis. Results: A total of 154 patients were included: 29 received BV-CHP, 72 received CHOP, and 53 received THP-COP. Overall, no significant differences were observed in PFS, OS, or ORR among the three treatment groups. In exploratory subgroup analyses, patients with bone marrow involvement who were treated with BV-CHP (n = 4) had significantly shorter PFS than those treated with CHOP (n = 17) or THP-COP (n = 15), whereas no significant difference in OS was observed. Conclusions: In this real-world multicenter cohort from the Gifu Hematology Study Group, frontline BV-CHP did not demonstrate a survival advantage over CHOP or THP-COP in unselected patients with PTCL. These findings suggest that THP-COP remains a reasonable first-line treatment option in routine clinical practice. The inferior PFS observed in patients with bone marrow involvement treated with BV-CHP should be interpreted cautiously and warrants further investigation.
SN - 1346-4280
SN - 1880-9952
ER -